Provided by Tiger Trade Technology Pte. Ltd.

Veru Inc.

2.34
+0.10004.46%
Post-market: 2.440.1000+4.27%19:06 EST
Volume:65.46K
Turnover:152.74K
Market Cap:37.56M
PE:-1.51
High:2.37
Open:2.24
Low:2.21
Close:2.24
52wk High:7.40
52wk Low:2.10
Shares:16.05M
Float Shares:14.48M
Volume Ratio:0.54
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5517
EPS(LYR):-1.5517
ROE:-61.92%
ROA:-49.21%
PB:2.05
PE(LYR):-1.51

Loading ...

Veru Inc. kündigt Veröffentlichung von Quartalsergebnissen und Geschäftsupdate an

Reuters
·
Feb 04

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

GlobeNewswire
·
Feb 04

Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting

Reuters
·
Feb 04

Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting

Reuters
·
Jan 29

Veru Initiated at Buy by Canaccord Genuity

Dow Jones
·
Dec 18, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Reuters
·
Dec 17, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse

Reuters
·
Dec 17, 2025

BUZZ-Veru rises after US FDA backs obesity drug combo plan

Reuters
·
Dec 17, 2025

Veru FY 2025 EPS $(1.55) Beats $(1.77) Estimate

Benzinga
·
Dec 17, 2025

Veru Inc. FY2025 net loss narrows to USD 22.7 million, down 40 percent

Reuters
·
Dec 17, 2025

Veru Inc - Company Plans to Initiate Phase 2 Plateau Clinical Study in Calendar Q1 2026

THOMSON REUTERS
·
Dec 17, 2025

Veru Inc - FY Net Loss From Cont Ops Decreased to $15.7 Mln or $1.07 per Share

THOMSON REUTERS
·
Dec 17, 2025

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

THOMSON REUTERS
·
Dec 17, 2025

Veru Inc - Received FDA Regulatory Clarity for Enobosarm in Combination With Glp-1 Ra

THOMSON REUTERS
·
Dec 17, 2025

Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings

Benzinga
·
Dec 16, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 15, 2025

Veru Inc. to Announce Fiscal Year 2025 Financial Results

Reuters
·
Dec 10, 2025

Veru to Report Fiscal Year 2025 Financial Results on December 17th

GlobeNewswire
·
Dec 10, 2025

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

GlobeNewswire
·
Dec 04, 2025

Veru Inc. unveils pipeline targeting obesity and cardiometabolic disease with novel drug combinations

Reuters
·
Nov 20, 2025